New hope for rare joint tumor: drug targets tough cases

NCT ID NCT04703322

First seen Mar 05, 2026 · Last updated May 13, 2026 · Updated 9 times

Summary

This study tests a drug called pexidartinib in 9 adults in Japan who have a rare, non-cancerous joint tumor (TGCT) that causes severe problems and cannot be helped by surgery. The goal is to see if the drug can shrink the tumor and improve joint movement, while checking for side effects. Participants take the drug by mouth and are monitored closely for safety and response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Kanazawa University Hospital

    Ishikawa, 920-8641, Japan

  • Kyushu University Hospital

    Fukuoka, 812-8582, Japan

  • Nagoya University Hospital

    Aichi, 466-8560, Japan

  • National Cancer Center Hospital

    Tokyo, 104-0045, Japan

  • National Hospital Organization Osaka National Hospital

    Osaka, 540-0006, Japan

  • Osaka International Cancer Institute

    Osaka, 541-8567, Japan

Conditions

Explore the condition pages connected to this study.